Get the Stockscreener App
38.32
10.38%
-4.44
Pre-market:
38.75
0.43
+1.12%
Uniqure Nv stock is traded at $38.32, with a volume of 4.22M.
It is down -10.38% in the last 24 hours and down -19.26% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$42.76
Open:
$42.42
24h Volume:
4.22M
Relative Volume:
2.82
Market Cap:
$2.66B
Revenue:
$18.09M
Net Income/Loss:
$-208.87M
P/E Ratio:
-10.91
EPS:
-3.5125
Net Cash Flow:
$-178.15M
1W Performance:
-13.09%
1M Performance:
-19.26%
6M Performance:
+152.44%
1Y Performance:
-19.33%
1-Day Range:
$36.82
$42.87
1-Week Range:
$36.82
$45.80
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
38.32 | 2.66B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
Why is uniQure stock sliding today? By Investing.com - Investing.com Australia
uniQure stock falls 5.57 percent as cash reaches USD 810.3 million - AD HOC NEWS
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure stock eyes key AMT-130 update as Huntington’s gene therapy advances - AD HOC NEWS
uniQure stock holds recent gains as Huntington’s gene therapy filing reshapes outlook - AD HOC NEWS
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Yahoo Finance
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - natlawreview.com
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
uniQure Submits BLA and MAA for AMT-130 Gene Therapy in Huntington's Disease - BioPharm International
QURE Submits Application for Gene Therapy for Huntington's Disease - The Globe and Mail
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - Moomoo
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $75 - moomoo.com
QURE Reinstated by William Blair -- Rating Set to Outperform - GuruFocus
Why is Uniqure NV stock gaining today? - Investing.com
uniQure seeks FDA accelerated nod for gene therapy (QURE) - Seeking Alpha
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says - Benzinga
Why is Uniqure NV stock gaining today? By Investing.com - Investing.com India
uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
QURE Looks 505.1% Overvalued on GF Value™ - GuruFocus
UniQure Submits BLA for AMT-130 in Huntington's Disease - marketscreener.com
uniQure submits BLA to FDA and MAA to MHRA for AMT-130 in Huntington’s disease - tradingview.com
uniQure Announces Submission of Biologics License - GlobeNewswire
Uniqure (QURE) Financials FY2025: Revenue $16.1M, Net Loss $199.0M | Income Statement & Balance Sheet - Stock Titan
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
RTW INVESTMENTS, LP Buys uniQure NV (QURE) -- Shares Look 531% O - GuruFocus
uniQure N.V. - Reuters
Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE - MarketBeat
uniQure (QURE) Advances 3.31% as Gene Therapy Optimism ReturnsDividend Growth Stocks - Vinanet
Responsive Playbooks and the QURE Inflection - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Uniqure NV (QURE) Stock News Today - TradingKey
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):